PLUS THERAPEUTICS INC (PSTV)

US72941H5090 - Common Stock

2.24  -0.01 (-0.44%)

After market: 2.25 +0.01 (+0.45%)

News Image
2 days ago - Plus Therapeutics Inc.

Plus Therapeutics Announces New Employment Inducement Grants

Plus Therapeutics Announces New Employment Inducement Grants...

News Image
4 days ago - InvestorPlace

PSTV Stock Earnings: Plus Therapeutics Beats EPS, Misses Revenue for Q1 2024

PSTV stock results show that Plus Therapeutics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.

News Image
4 days ago - BusinessInsider

PSTV Stock Earnings: Plus Therapeutics Beats EPS, Misses Revenue for Q1 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Plus Therapeutics (NASDAQ:PSTV) just reported results for the first quarter of ...

News Image
4 days ago - Plus Therapeutics Inc.

Plus Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

Plus Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights...

News Image
7 days ago - Plus Therapeutics Inc.

Plus Therapeutics to Announce First Quarter Financial Results and Host Conference Call on May 15, 2024

Plus Therapeutics to Announce First Quarter Financial Results and Host Conference Call on May 15, 2024 ...

News Image
11 days ago - Plus Therapeutics Inc.

Plus Therapeutics to Host Investor Call to Discuss Leptomeningeal Cancer Related Acquisition and Topline Clinical Trial Data from the FORESEE Trial

Plus Therapeutics to Host Investor Call to Discuss Leptomeningeal Cancer Related Acquisition and Topline Clinical Trial Data from the FORESEE Trial...

News Image
14 days ago - Plus Therapeutics Inc.

Plus Therapeutics Announces Private Placement Financing of up to $18 Million

Plus Therapeutics Announces Private Placement Financing of up to $18 Million...

News Image
a month ago - Plus Therapeutics Inc.

Plus Therapeutics Receives $3 Million Award Recommendation from the United States Department of Defense

Plus Therapeutics Receives $3 Million Award Recommendation from the United States Department of Defense...

News Image
a month ago - Plus Therapeutics Inc.

Neuro-Oncologist Andrew Brenner, M.D., Ph.D. and Barbara Blouw, Ph.D. Join Plus’ Management Team

The addition of both Dr. Brenner and Dr. Blouw substantially expands Plus internal expertise in key areas Dr. Brenner will maintain his academic...

News Image
3 months ago - InvestorPlace

PSTV Stock Earnings: Plus Therapeutics Beats EPS, Beats Revenue for Q4 2023

PSTV stock results show that Plus Therapeutics beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023.

News Image
3 months ago - BusinessInsider

PSTV Stock Earnings: Plus Therapeutics Beats EPS, Beats Revenue for Q4 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Plus Therapeutics (NASDAQ:PSTV) just reported results for the fourth quarter of...

News Image
3 months ago - Plus Therapeutics Inc.

Plus Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

Began enrollment of the 5th of an anticipated 7 planned dosing cohorts for the ReSPECT-LM Phase 1 dose escalation trial with rhenium (186Re) obisbemeda for...

News Image
5 months ago - Seeking Alpha

Plus sees an additional $6.9M in grant revenue in 2024 (NASDAQ:PSTV)

Plus Therapeutics expects an additional $6.9 million in grant revenue in 2024, along with a lower interest rate and deferred principal payments on a debt...

News Image
5 months ago - Plus Therapeutics Inc.

Plus Updates Financial and Cash Guidance for 2024

Plus Receives $3.3M in grant revenue in Q4 2023 Forecasts additional $6.9M of grant revenue for 2024 Enters into debt restructuring deal with Pershing...

News Image
6 months ago - Seeking Alpha

Plus Therapeutics files to sell ordinary shares, warrants (NASDAQ:PSTV)

Plus Therapeutics files prospectus for sale of ordinary shares and pre-funded warrants. This is not an offer to sell securities.

News Image
6 months ago - Plus Therapeutics Inc.

Plus Therapeutics to Host Virtual KOL Event on New Phase 2 ReSPECT-GBM Data in Recurrent Glioblastoma Presented at the Society for NeuroOncology (SNO) Conference on Monday, November 20, 2023

AUSTIN, Texas, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company...

News Image
7 months ago - Plus Therapeutics Inc.

Plus Therapeutics Granted U.S. FDA Orphan Drug Designation to Rhenium (186Re) Obisbemeda for the Treatment of Breast Cancer with Leptomeningeal Metastases

AUSTIN, Texas, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company...

News Image
7 months ago - InvestorPlace

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

We're starting off Wednesday with a breakdown of the biggest pre-market stock movers investors will want to keep track of today!

News Image
7 months ago - Seeking Alpha

Plus Therapeutics stock jumps on $500,000 share repurchase program (NASDAQ:PSTV)

Plus Therapeutics (PSTV) approves share repurchase program worth $500k, leading to a 4.1% rise in extended trading.

News Image
7 months ago - Plus Therapeutics Inc.

Plus Therapeutics Announces Share Repurchase Program

AUSTIN, Texas, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company...

News Image
7 months ago - Plus Therapeutics Inc.

Plus Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights

New survival data from 15 patients in the Phase 2 ReSPECT-GBM trial of rhenium (186Re) obisbemeda in recurrent glioblastoma (rGBM) will be presented at SNO Annual Meeting on November 17th; Company will also host a Key Opinion Leader (KOL) event following the meeting to discuss the results

News Image
7 months ago - Plus Therapeutics Inc.

Plus Therapeutics to Present at the Society for NeuroOncology Annual Meeting and will Host Key Opinion Leader Webinar

Update on the ReSPECT-GBM Trial, including Phase 2, with Rhenium-186 Obisbemeda in Recurrent Glioblastoma will be Presented at SNO Annual Meeting...

News Image
7 months ago - Plus Therapeutics Inc.

Plus Therapeutics to Announce Third Quarter 2023 Financial Results and Host Conference Call on October 31, 2023

AUSTIN, Texas, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company...

News Image
7 months ago - Plus Therapeutics Inc.

Plus Therapeutics Completes Dosing in Cohort 4 of ReSPECT-LM Phase 1 Clinical Trial of Rhenium (¹⁸⁶Re) Obisbemeda in Leptomeningeal Metastases

Cohort 4 of the ReSPECT-LM Phase 1 dose escalation trial is the first of 4 planned cohorts in Part B; the Company anticipates moving into Cohort 5...

News Image
7 months ago - Plus Therapeutics Inc.

Plus Therapeutics to Participate in the Jones Trading Healthcare Summit and ThinkEquity Conference in October

AUSTIN, Texas, Oct. 09, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company...